NCT02887573

Brief Summary

Colon capsule endoscopy(CCE) is a new diagnostic method of colonic lesions.It has advantages of no requirement for sedation and air insufflation.The bowel preparation has a closely relationship with yield of diagnosing diseases.Bowel preparation of CCE is not only to clean the colon but also to promote capsule propulsion.Now there is not an optimal method for CCE.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
62

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2014

Longer than P75 for phase_4

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
2.6 years until next milestone

First Submitted

Initial submission to the registry

August 20, 2016

Completed
13 days until next milestone

First Posted

Study publicly available on registry

September 2, 2016

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2017

Completed
Last Updated

February 7, 2017

Status Verified

February 1, 2017

Enrollment Period

3.5 years

First QC Date

August 20, 2016

Last Update Submit

February 4, 2017

Conditions

Keywords

Bowel preparationColorectal polypsColon capsule endoscopy

Outcome Measures

Primary Outcomes (1)

  • Bowel Cleansing Level of Two Different Bowel Preparation Methods

    The first 32 patients adopted a low fiber diet two days before the CCE procedure. Bowel preparation included the ingestion of 2L polyethyleneglycol in the evening before test day and 2L PEG in the morning on the test day. The subsequent 30 patients were received free-residue Nutrients。Then they ingested 2L PEG between 5:00 and 7.00 am of the examination day. The capsule was scheduled at 8:30 am. When the capsule reached the small bowel, 0.75L PEG was used as first booster. If the capsule had not been excreted 3 hours later, the patients was received 0.5L PEG.

    an expected average of 1 months from study procedure

Secondary Outcomes (4)

  • Accuracy parameters:assessment the yield of detection of polyps ≥6mm and ≥10mm;

    an expected average of 1 months from study procedure

  • The gastrointestinal tract transit times and the colonic transit times between two different bowel preparation methods for CCE;

    an expected average of 1 months from study procedure

  • Colon capsule excretion rate between two different bowel preparation methods;

    an expected average of 1 months from study procedure

  • Adverse events between two different bowel preparation methods.

    the PillCam procedure day

Study Arms (2)

Free-residue nutrients+PEG

EXPERIMENTAL

Diet: Free-residue nutrients Free-residue nutrient will be given when the patients are hungry before the two days of the capsule day.There are no other diet in this arm. Drug: PEG 2L PEG are used at 05:00-07:00 the morning of the test. Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists. Procedure: Colonoscopy On the following day of the test.All participants will undergo therapeutic colonoscopy.

Drug: Free-residue nutrientsProcedure: Colon capsule endoscopyDrug: 2L PEGDrug: PEGDrug: Mosapride citrate

Low fiber diet+PEG

EXPERIMENTAL

Diet: Low fiber diet Before the two days of the capsule day,when the patients hungry,low fiber diet wiil be given. Drug: PEG 4L PEG are used at 21:00-23:00 the night before the test and 05:00-07:00 the morning of the test. Drug: Mosapride citrate The patients will take 5mg mosapride citrate at 8:00. Drug:PEG 0.75L and 0.50L PEG are administered as boosters for patients. Procedure: Colon capsule endoscopy The colon capsule will be ingested at 08:30 the day of the test.The images will be reviewed by two experienced endoscopists. Procedure: Colonoscopy On the following day of the test,All participants will undergo therapeutic colonoscopy.

Drug: Low fiber dietProcedure: Colon capsule endoscopyDrug: 4L PEGDrug: PEGDrug: Mosapride citrate

Interventions

This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.

Free-residue nutrients+PEG

Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.

Low fiber diet+PEG

In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.

Free-residue nutrients+PEGLow fiber diet+PEG
2L PEGDRUG

2L PEG are laxatives for experiment group.

Also known as: polyethylene glycol
Free-residue nutrients+PEG
4L PEGDRUG

4L PEG are laxatives in the control group.

Also known as: polyethylene glycol
Low fiber diet+PEG
PEGDRUG

These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.

Also known as: polyethylene glycol
Free-residue nutrients+PEGLow fiber diet+PEG

5mg mosapride citrate are used to promote gastric motivity.

Free-residue nutrients+PEGLow fiber diet+PEG

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years of age.
  • underwent a diagnostic OC that demonstrated colorectal polyps that required endoscopic treatment.

You may not qualify if:

  • dysphagia/swallowing disorder
  • prior major abdominal surgery of the gastrointestinal tract, known or suspected bowel obstruction
  • cardiac pacemaker/implanted electromedical device
  • pregnant or nursing women
  • any allergy or contraindication to the drugs used in the study.
  • refused to sign a informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

EndoscopyPolyethylene Glycolsmosapride

Intervention Hierarchy (Ancestors)

Diagnostic Techniques, SurgicalDiagnostic Techniques and ProceduresDiagnosisMinimally Invasive Surgical ProceduresSurgical Procedures, OperativeEthylene GlycolsGlycolsAlcoholsOrganic ChemicalsPolymersMacromolecular SubstancesBiomedical and Dental MaterialsManufactured MaterialsTechnology, Industry, and Agriculture

Study Officials

  • Wu Kaichun, phD

    Xijing Hospital of Digestive Diseases

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
President of Xijing Hospital of Digestive Diseases

Study Record Dates

First Submitted

August 20, 2016

First Posted

September 2, 2016

Study Start

January 1, 2014

Primary Completion

July 1, 2017

Study Completion

July 1, 2017

Last Updated

February 7, 2017

Record last verified: 2017-02